Retatrutide + GHK-Cu + ipamorelin stack

This article is for educational purposes only and does not constitute medical advice. None of the compounds discussed are approved for general consumer use in most jurisdictions. Consult a qualified clinician before starting, combining, or adjusting any peptide regimen.

A recurring question in peptide communities: can you run retatrutide alongside GHK-Cu and a growth hormone secretagogue pair like ipamorelin with CJC-1295 No DAC? The literature does not study these compounds together, so any interaction data is absent. What research does provide is a picture of how each compound works individually, which is the starting point for any conversation with a clinician.^[1]

Retatrutide: mechanism and current status

Retatrutide is an investigational triple receptor agonist that activates the GLP-1, GIP, and glucagon receptors simultaneously.^[1] In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants receiving the highest dose (12 mg weekly by subcutaneous injection) achieved a mean 24.2% body-weight reduction at 48 weeks. At that dose, every participant reached at least 5% loss and 83% reached at least 15% loss.^[1]

The glucagon receptor component separates retatrutide from dual agonists like tirzepatide: glucagon receptor activation raises energy expenditure and drives fat oxidation through pathways the GLP-1 receptor alone does not reach. Gastrointestinal adverse effects, dose-dependent and mostly mild to moderate, were the main safety signal in Phase 2.^[1]

As of August 2026 retatrutide is not approved by the FDA, the EMA, or the MHRA. It remains under Phase 3 investigation through the TRIUMPH programme. The FDA has issued warning letters to compounding pharmacies selling unauthorised retatrutide, stating the compound cannot be used in compounding under federal law. Per-country regulatory status is on the retatrutide regulation pages.

GHK-Cu: what the literature says

GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycine-histidine-lysine. The compound appears in human plasma, saliva, and urine, and its plasma concentration declines with age.^[2] Laboratory and clinical work on topical GHK-Cu preparations has shown acceleration of wound healing, stimulation of collagen and glycosaminoglycan synthesis, and improvements in skin elasticity and firmness.^[2]

A separate cell-culture study found that even the copper-free GHK tripeptide enhances keratinocyte stem cell markers including integrin expression (alpha-6 and beta-1) and the transcription factor p63, pointing to a direct effect on epidermal renewal that does not depend on the copper ion.^[3]

Hair is frequently mentioned in community discussions on GHK-Cu. The Pickart et al. 2015 review notes that the compound accelerated healing in hair follicle tissue in animal models.^[2] Controlled human trial data specifically measuring hair density or growth rate from systemic injectable GHK-Cu administration is limited. Topical cosmetic formulations remain the best-studied application.

Ipamorelin and CJC-1295 No DAC

Ipamorelin is a pentapeptide growth hormone secretagogue that works through the ghrelin/GHRP receptor. A 1998 study characterised it as the first GHRP-receptor agonist with a selectivity for GH release comparable to that of GHRH itself: at doses 200 times the effective GH-stimulating dose, it produced no significant elevation of ACTH, cortisol, FSH, LH, prolactin, or TSH.^[4] That selective profile is why ipamorelin appears frequently in the research literature in preference to older secretagogues like GHRP-2 or GHRP-6.

CJC-1295 No DAC, sometimes called modified GRF 1-29, is a stabilized analog of the first 29 amino acids of GHRH. Unlike the DAC (Drug Affinity Complex) version, it does not bind albumin and has a shorter half-life, producing GH pulses rather than prolonged tonic elevation. The original CJC-1295 with DAC trial in healthy adults documented GH increases of 2- to 10-fold lasting six or more days and IGF-I increases of 1.5- to 3-fold lasting nine to eleven days after a single dose, with no serious adverse reactions at the doses studied.^[5] The No DAC variant is designed to produce shorter, more physiological-looking pulses.

Does buying ipamorelin and CJC-1295 No DAC separately matter?

Multiple suppliers sell these compounds as separate vials rather than a pre-mixed combination. From a pharmacological standpoint, the receptor targets do not change based on packaging. CJC-1295 No DAC primes pituitary somatotrophs through the GHRH receptor; ipamorelin triggers the GH pulse through the ghrelin/GHRP receptor. Whether you reconstitute and inject from one vial or two, the mechanism is the same. No published trials directly compare co-mixed versus sequentially injected protocols.

The missing interaction data

Retatrutide's glucagon receptor activity raises a specific question: glucagon can stimulate GH secretion from the pituitary, so adding exogenous GH secretagogues to a background of glucagon receptor agonism might, in theory, produce additive stimulation of the GH axis. The Phase 2 retatrutide trial does not report GH or IGF-1 endpoints, and no published study has evaluated retatrutide given together with ipamorelin or any GHRH analog.^[1] This is a genuine data gap, not a reason to assume the combination is safe.

Each compound in this potential stack has a distinct mechanism and distinct evidence base. Retatrutide is one of the most studied investigational weight-loss peptides currently in the literature. GHK-Cu has a reasonable topical wound-healing evidence base, with more limited data on systemic or injectable use. Ipamorelin and CJC-1295 No DAC each have published preclinical and some human pharmacokinetic data supporting GH-secretagogue activity. What does not exist is any published data on how all three behave together in humans. Discuss that gap with a clinician before combining them. See also the ipamorelin overview for the regulatory picture on that compound.